Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A2 | O15244 | 1/20 | 0.32 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13126722 | 1.00 | SLC22A2 (0.32) | SLC22A2SLC47A1MAPTMEN1CYP1A2 | |
| SCHEMBL8090288 | 0.83 | SLC22A2 (0.30) | SLC22A2SLC47A1 | |
| SCHEMBL12765492 | 0.75 | — | — | |
| SCHEMBL25509289 | 0.74 | SLC22A2 (0.32) | SLC22A2SLC47A1MAPTMEN1CYP1A2 | |
| SCHEMBL12308339 | 0.74 | SLC22A2 (0.32) | SLC22A2SLC47A1MAPTMEN1CYP1A2 | |
| SCHEMBL25509281 | 0.74 | GRIN1 (0.50) | SLC22A2SLC47A1MAPTMEN1CYP1A2 | |
| SCHEMBL9920198 | 0.74 | EPHX2 (0.40) | SLC22A2SLC47A1 | |
| SCHEMBL13126723 | 0.74 | SLC22A2 (0.32) | SLC22A2SLC47A1MAPTMEN1CYP1A2 | |
| SCHEMBL25509293 | 0.74 | EPHX2 (0.40) | SLC22A2SLC47A1 | |
| SCHEMBL12765505 | 0.71 | THRB (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | GENENTECH, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| US-11655238-B2 | MMPL3 inhibitors, compositions and uses thereof | SHANGHAITECH UNIVERSITY (CN) | 2023-05-23 | — | — | US | disclosed |
| US-10005724-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
| US-20170002017-A1 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-05 | — | — | US | disclosed |
| US-8952169-B2 | N-substituted benzamides and methods of use thereof | XENON PHARMACEUTICALS INC. (CA) | 2015-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | SLC22A2 1221/4885SLC47A1 431/4885MAPT 4404/4885 |
| US-11655238-B2 | MMPL3 inhibitors, compositions and uses thereof | TIMP3, AFG3L2, MMP3 | SLC22A2 2853/4885SLC47A1 380/4885MAPT 3288/4885 |
| US-20170002017-A1 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, SNRPD2 | SLC22A2 1487/4885SLC47A1 2600/4885MAPT 4699/4885 |
| US-10005724-B2 | Therapeutic compounds and methods of use thereof | RDX, C1R, MTX1 | SLC22A2 1221/4885SLC47A1 431/4885MAPT 4404/4885 |
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | CACNA1I, CACNA1B, CACNA1C | SLC22A2 261/4885SLC47A1 227/4885MAPT 3123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.